Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9UBF8

UPID:
PI4KB_HUMAN

ALTERNATIVE NAMES:
NPIK; PI4K92; PI4KIII

ALTERNATIVE UPACC:
Q9UBF8; B4DGI2; O15096; P78405; Q5VWB9; Q5VWC0; Q5VWC1; Q9BWR6

BACKGROUND:
The Phosphatidylinositol 4-kinase beta, with aliases NPIK and PI4K92, is central to the production of inositol-1,4,5-trisphosphate, a key second messenger in cellular signaling. It regulates critical cellular functions, including mitotic Golgi disintegration/reorganization and membrane trafficking. Additionally, PI4KIII is essential for inner ear development and plays a significant role in microbial infections, being necessary for Aichi virus RNA replication and SARS-CoV spike-mediated cell entry.

THERAPEUTIC SIGNIFICANCE:
PI4KIII's association with deafness, autosomal dominant, 87 (DFNA87), a condition marked by severe sensorineural hearing loss, underscores its therapeutic potential. Exploring PI4KIII's functions and mechanisms could lead to innovative treatments for hearing impairments and offer new avenues for antiviral therapies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.